References

ateroskleroz

Атеросклероз

Ateroscleroz

2078-256X2949-3633

НИИТПМ-филиал ИЦиГ СО РАН

10.52727/2078-256X-2025-21-1-60-91

ateroskleroz-1102

Research Article

ОБЗОРЫ ЛИТЕРАТУРЫ

LITERATURE REVIEWS

Цитокиновые факторы роста в регуляции ангиогенеза и атерогенного воспаления в сосудистой стенке. Аналитический обзор. Часть 1

Cytokine growth factors in the regulation of angiogenesis and atherogenic inflammation in the vascular wall. The role of polysaccharide polymers. Analytical review. Part 1

https://orcid.org/0000-0002-1221-6373

Большаков

И. Н.

Bolshakov

I. N.

Игорь Николаевич Большаков, д-р мед. наук, проф. кафедры оперативной хирургии и топографической анатомии

660022, г. Красноярск, ул. Партизана Железняка, 1

Igor N. Bolshakov, doctor of medical sciences, professor of the operative surgery and topographic anatomy department

1, Partizana Zheleznyaka st., Krasnoyarsk, 660022

bol.bol@mail.ru

Шиндякин

Д. В.

Shindyakin

D. V.

Дмитрий Васильевич Шиндякин, студент педиатрического факультета

660022, г. Красноярск, ул. Партизана Железняка, 1

Dmitry V. Shindyakin, student of the pediatric faculty

1, Partizana Zheleznyaka st., Krasnoyarsk, 660022

shindyakin.d@gmail.com

https://orcid.org/0000-0001-5416-7904

Кириченко

А. К.

Kirichenko

A. K.

Андрей Константинович Кириченко, д-р мед. наук, проф. кафедры патологической анатомии

660022, г. Красноярск, ул. Партизана Железняка, 1

Andrey K. Kirichenko, doctor of medical sciences, professor of the pathological anatomy department

1, Partizana Zheleznyaka st., Krasnoyarsk, 660022

Бахшян

В. А.

Bahshyan

V. A.

Валентина Артуровна Бахшян, студент лечебного факультета

660022, г. Красноярск, ул. Партизана Железняка, 1

Valentina A. Bahshyan, student of the faculty of medicine

1, Partizana Zheleznyaka st., Krasnoyarsk, 660022

v.bahshyan@mail.ru

https://orcid.org/0000-0002-5839-1732

Архипкин

С. В.

Arkhipkin

S. V.

Сергей Викторович Архипкин, старший преподаватель кафедры оперативной хирургии и топографической анатомии

660022, г. Красноярск, ул. Партизана Железняка, 1

Sergey V. Arkhipkin, senior lecturer of operative surgery and topographic anatomy department

1, Partizana Zheleznyaka st., Krasnoyarsk, 660022

sergey1510@ya.ru

Федеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Министерства здравоохранения Российской Федерации»Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky of Ministry of Health of Russian Federation

2025

30032025

2116091

2025

Большаков И.Н., Шиндякин Д.В., Кириченко А.К., Бахшян В.А., Архипкин С.В.

Bolshakov I.N., Shindyakin D.V., Kirichenko A.K., Bahshyan V.A., Arkhipkin S.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://ateroskleroz.elpub.ru/jour/article/view/1102

Целью обзора является оценка терапевтических возможностей локальной активации ангиогенеза и прерывания атерогенного воспаления при реконструкции слоев артериальной стенки методом введения полисахаридных полимеров в пара-адвентициальную зону кровеносных сосудов. Концепция обзора строится на гипотезе восстановления баланса провоспалительных и атеропротекторных цитокиновых факторов роста при использовании биополимеров. Согласно данным литературы реконструкция адвентициального слоя артериальной стенки с применением гидрогелей полисахаридного ряда, обладающих высоким сродством к холестерину, обусловливает формирование дополнительного внеклеточного матрикса за пределами интимальной и средней зон магистральной артерии и перехода холестериновой массы из интимальной зоны в околоадвентициальное пространство. Создание продуктивного воспаления в зоне адвентиции с помощью биополимеров может служить одним из эффективных способов деградации ранних мягких атеросклеротических бляшек. Рассматривается возможность удаления мягких атеросклеротических бляшек из интимального пространства магистральных артерий методом обширной имплантации в фасциальный футляр сосудов полисахаридных гидрогелей, образующих внеклеточный матрикс второго уровня. Анализ литературы, соответствующей концепции, проводился с использованием баз данных WoS, Scopus, PubMed, DOAJ, Embase, Ei Compendex, преимущественно за последние 8 лет. Обзор позволяет составить представление о молекулярных процессах, протекающих в стенке сосуда при развитии атерогенного воспаления и выявить признаки реконструкции сосудистой стенки при экзогенной имплантации биополимеров. В сосудистой стенке цитокиновые факторы роста сопряжены с природными или синтетическими биоматериалами. Иммобилизованные факторы доступны для клеток, которые вступают в контакт с матрицей, и обеспечивают точно локализованный сигнал для контроля судьбы клеток. Многообещающим подходом для стимулирования ангиогенеза являются биополимерные инъекционные каркасы. Клеточная миграция из интимы и медии может быть активирована благодаря электростатическому градиенту в присутствии сульфатированного полимера, образующего аффинные комплексы с холестерином и липопротеинами низкой плотности (ЛПНП). Высокая аффинность полисахаридных полимеров к холестерину и ЛПНП, а также активная васкуляризация дополнительного экстраклеточного матрикса провоцируют концентрационный градиент холестерина, направленный в сторону гидрогелевой «рубашки». Эффект оттока холестерина может стать основой нового подхода в терапии патологии магистральных сосудов.

The aim of the review is the determining of the therapeutic possibilities of local activation of angiogenesis and degradation of atherogenic inflammation during reconstruction of arterial wall layers under conditions of wide implantation of polysaccharide polymers in the para-adventitial zone. The concept of the analytical review is based on the hypothesis of improving the balance between pro-inflammatory and atheroprotective cytokine growth factors when using biopolymers. The analysis of the literature indicates an active direct intervention in the reconstruction of the adventitial layer of the arterial wall using polysaccharide hydrogels with a high affinity for cholesterol, conditions are created for the formation of an additional extracellular matrix outside the intimal and medial zones of the main artery and the reversal of the cholesterol mass from the intimal zone to the para-adventitial space. The creation of productive inflammation in the adventitial zone using biopolymers can be one of the effective ways to degrade early soft atheromatous plaques. Publications indicate the possibility of extracting soft atheromatous plaques from the intimal space of major arteries by wide implantation of polysaccharide hydrogels into the fascial sheath of vessels with the formation of a second-level extracellular matrix. The analysis of literary sources according to the concept was carried out using databases indexed by WoS, Scopus, PubMed, DOAJ, Embase, Ei Compendex mainly for the last 8 years.The literature review allows us to form a modern understanding of the molecular processes occurring in the vessel wall during the development of atherogenic inflammation in an experiment on animals receiving a cholesterol diet, to indicate signs of vascular wall reconstruction with exogenous implantation of biopolymers. In the vascular wall, there is a conjugation of cytokine growth factors with natural or synthetic biomaterials. Immobilized factors will be available to cells that come into contact with the matrix, providing a highly localized signal to control cell fate. Injectable scaffolds are a promising approach for stimulating angiogenesis. Cell migration from the intima and media can be activated by an electrostatic gradient in the presence of a sulfated polymer and lead to the formation of affinity complexes with cholesterol. The high affinity of polysaccharide polymers for cholesterol and LDL, active vascularization of the additional extracellular matrix provoke a gradient of cholesterol translation towards the hydrogel “shirt”. The effect of cholesterol outflow can provide a new therapeutic approach to the pathology of the main vessels.

ангиогенезатерогенезфакторы ростабиополимерыадвентицияэкстраклеточный матрикс

angiogenesisatherogenesisgrowth factorsbiopolymersadventitiaextracellular matrix

Работа выполнена при поддержке гранта № 16-44-240506 Российского фонда фундаментальных исследований, гранта № 2022030908453 Красноярского краевого фонда поддержки научной и научно-технической деятельности, гранта Красноярского краевого инновационно-технологического бизнес-инкубатора, инвестиции компании «Альфа-Хим» (г. Красноярск), компании «Биоимплант» (г. Красноярск) (соглашение № 01/11/П от 11.01.2018) и Центра лабораторных технологий АВС (соглашение № 642-19 от 17.09.2019). Авторы благодарят Хоржевского В.А., руководителя патолого-анатомического отдела Красноярского клинического онкологического центра им. А.И. Крыжановского, за консультации по забору экспериментального морфологического материала, изготовление гистологических срезов тканей, за консультации по анализу морфологических структур.

The work was supported by grant No. 16-44-240506 from the Russian Foundation for Basic Research, grant No. 2022030908453 from the Krasnoyarsk Regional Fund for Support of Scientific and Scientific and Technical Activities, grant from the Krasnoyarsk Regional Innovative and Technological Business Incubator, and investments from AlfaChem company (Krasnoyarsk), Bioimplant company (Krasnoyarsk) (agreement No. 01/11/P from 11.01.2018), and Center for Laboratory Technologies ABC (agreement No. 642-19 from 17.09.2019). The author thanks Khorzhevsky V.A., head of the pathological anatomy department of the Krasnoyarsk Clinical Oncology Center named after A.I. Kryzhanovsky, for consultations on collecting experimental morphological material, preparing histological tissue sections, and for consultations on the morphological structures analysis.

References1

Abu Dabrh A.M., Steffen M.W., Undavalli C., Asi N., Wang Z., Elamin M.B., Conte M.S., Murad M.H. The natural history of untreated severe or critical limb ischemia. J. Vasc. Surg., 2015; 62 (6): 1642–1651. doi: 10.1016/j.jvs.2015.07.065

Han J., Luo L., Marcelina O., Kasim V., Wu S. Therapeutic angiogenesis-based strategy for peripheral artery disease. Theranostics, 2022; 12 (11): 5015–5033. doi: 10.7150/thno.74785

Riley C.M., Fuegy P.W., Firpo M.A., Shu X.Z., Prestwich G.D., Peattie R.A. Stimulation of in vivo angiogenesis using dual growth factor-loaded cross-linked glycosaminoglycan hydrogels. Biomaterials, 2006; 27 (35): 5935–5943. doi: 10.1016/j.biomaterials.2006.08.029

Chiu L.L., Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials, 2010; 31 (2): 226–241. doi: 10.1016/j.biomaterials.2009.09.039

Layman H., Li X., Nagar E., Vial X., Pham S.M., Andreopoulos F.M. Enhanced angiogenic efficacy through controlled and sustained delivery of FGF-2 and G-CSF from fibrin hydrogels containing ionic-albumin microspheres. J. Biomater. Sci. Polym. Ed., 2012; 23 (1-4): 185–206. doi: 10.1163/092050610X546417

Roberts J.J., Farrugia B.L., Green R.A., Rnjak-Kovacina J., Martens P.J. In situ formation of poly(vinyl alcohol)-heparin hydrogels for mild encapsulation and prolonged release of basic fibroblast growth factor and vascular endothelial growth factor. J. Tissue Eng., 2016; 7: 2041731416677132. doi: 10.1177/2041731416677132

Zieris A., Chwalek K., Prokoph S., Levental K.R., Welzel P.B., Freudenberg U., Werner C. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J. Control. Release, 2011; 156 (1): 28–36. doi: 10.1016/j.jconrel.2011.06.042

Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature, 2000; 407 (6801): 242–248. doi: 10.1038/35025215

Li B., Xiu R. Angiogenesis: from molecular mechanisms to translational implications. Clin. Hemorheol. Microcirc., 2013; 54 (4): 345–355. doi: 10.3233/CH-121647

Jansen P.L., Rosch R., Jansen M., Binnebösel M., Junge K., Alfonso-Jaume A., Klinge U., Lovett D.H., Mertens P.R. Regulation of MMP-2 gene transcription in dermal wounds. J. Invest. Dermatol., 2007; 127 (7): 1762–1767. doi: 10.1038/sj.jid.5700765

Zhang J., Kasim V., Xie Y.D., Huang C., Sisjayawan J., Dwi Ariyanti A., Yan X.S., Wu X.Y., Liu C.P., Yang L., Miyagishi M., Wu S.R. Inhibition of PHD3 by salidroside promotes neovascularization through cell-cell communications mediated by muscle-secreted angiogenic factors. Sci. Rep., 2017; 7: 43935. doi: 10.1038/srep43935

Luo L.L., Han J.X., Wu S.R., Kasim V. Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function. Acta Pharmacol. Sin., 2022; 43 (10): 2636–2650. doi: 10.1038/s41401-022-00889-4

Liu C., Han J., Marcelina O., Nugrahaningrum D.A., Huang S., Zou M., Wang G., Miyagishi M., He Y., Wu S., Kasim V. Discovery of salidroside-derivated glycoside analogues as novel angiogenesis agents to treat diabetic hind limb ischemia. J. Med. Chem., 2022; 65 (1): 135–162. doi: 10.1021/acs.jmedchem.1c00947

Davidson S.M. FAM3A – A mitochondrial route to the stimulation of angiogenesis? EBioMedicine, 2019; 43: 3–4. doi: 10.1016/j.ebiom.2019.04.033

Chapanian R., Amsden B.G. Combined and sequential delivery of bioactive VEGF165 and HGF from poly(trimethylene carbonate) based photo-crosslinked elastomers. J. Control. Release, 2010; 143 (1): 53–63. doi: 10.1016/j.jconrel.2009.11.025

Fagiani E., Christofori G. Angiopoietins in angiogenesis. Cancer Lett., 2013, 328 (1): 18–26. doi: 10.1016/j.canlet.2012.08.018

Sakurai T., Kudo M. Signaling pathways governing tumor angiogenesis. Oncology, 2011; 81, Suppl 1: 24– 29. doi: 10.1159/000333256

Payne L.B., Tewari B.P., Dunkenberger L., Bond S., Savelli A., Darden J., Zhao H., Willi C., Kanodia R., Gude R., Powell M.D., Oestreich K.J., Sontheimer H., Dal-Pra S., Chappell J.C. Pericyte progenitor coupling to the emerging endothelium during vasculogenesis via connexin 43. Arterioscler. Thromb. Vasc. Biol., 2022; 42 (4): 96–114. doi: 10.1161/ATVBAHA.121.317324

Kruse K., Lee Q.S., Sun Y., Klomp J., Yang X., Huang F., Sun M.Y., Zhao S., Hong Z., Vogel S.M., Shin J.W., Leckband D.E., Tai L.M., Malik A.B., Komarova Y.A. N-cadherin signaling via Trio assembles adherens junctions to restrict endothelial permeability. J. Cell. Biol., 2019; 218 (1): 299–316. doi: 10.1083/jcb.201802076

Moccia F., Negri S., Shekha M., Faris P., Guerra G. Endothelial Ca2+ signaling, angiogenesis and vasculogenesis: just what it takes to make a blood vessel. Int. J. Mol. Sci., 2019; 20 (16): 3962. doi: 10.3390/ijms20163962

Annex B.H. Therapeutic angiogenesis for critical limb ischaemia. Nat. Rev. Cardiol., 2013; 10 (7): 387–396. doi: 10.1038/nrcardio.2013.0

Hoeben A., Landuyt B., Highley M.S., Wildiers H., van Oosterom A.T., de Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev., 2004; 56 (4): 549–580. doi: 10.1124/pr.56.4.3

Braghirolli D.I., Helfer V.E., Chagastelles P.C., Dalberto T.P., Gamba D., Pranke P. Electrospun scaffolds functionalized with heparin and vascular endothelial growth factor increase the proliferation of endothelial progenitor cells. Biomed. Mater., 2017; 12 (2): 025003. doi: 10.1088/1748-605X/aa5bbc

Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer, 2010; 10 (7): 505–514. doi: 10.1038/nrc2868

Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic. Biol. Med., 2018; 117: 76–89. doi: 10.1016/j.freeradbiomed.2018.01.024

Kivelä R., Bry M., Robciuc M.R., Räsänen M., Taavitsainen M., Silvola J.M., Saraste A., Hulmi J.J., Anisimov A., Mдyränpää M.I., Lindeman J.H., Eklund L., Hellberg S., Hlushchuk R., Zhuang Z.W., Simons M., Djonov V., Knuuti J., Mervaala E., Alitalo K. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol. Med., 2014; 6 (3): 307–321. doi: 10.1002/emmm.201303147

Groppa E., Brkic S., Bovo E., Reginato S., Sacchi V., di Maggio N., Muraro M.G., Calabrese D., Heberer M., Gianni-Barrera R., Banfi A. VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGFβ1 paracrine axis. EMBO Mol. Med., 2015; 7 (10): 1366–1384. doi: 10.15252/emmm.201405003

Grunewald M., Kumar S., Sharife H., Volinsky E., Gileles-Hillel A., Licht T., Permyakova A., Hinden L., Azar S., Friedmann Y., Kupetz P., Tzuberi R., Anisimov A., Alitalo K., Horwitz M., Leebhoff S., Khoma O.Z., Hlushchuk R., Djonov V., Abramovitch R., Tam J., Keshet E. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science, 2021; 373 (6554): eabc8479. doi: 10.1126/science.abc8479

Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., Kettunen M.I., Kholová I., Kauppinen R.A., Achen M.G., Stacker S.A., Alitalo K., Ylä-Herttuala S. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res., 2003; 92 (10): 1098–1106. doi: 10.1161/01.RES.0000073584.46059.E3

Wu M., Pokreisz P., Swinnen M., Caluwe E., Gillijns H., Vanden Driessche N., Casazza A., Verbeken E., Collen D., Janssens S. Sustained placental growth factor-2 treatment does not aggravate advanced atherosclerosis in ischemic cardiomyopathy. J. Cardiovasc. Transl. Res., 2017; 10 (4): 348–358. doi: 10.1007/s12265-017-9742-4

Goonoo N., Bhaw-Luximon A. Mimicking growth factors: role of small molecule scaffold additives in promoting tissue regeneration and repair. RSC Adv., 2019; 9 (32): 18124–18146. doi: 10.1039/c9ra02765c

Risau W. Angiogenic growth factors. Prog. Growth. Factor Res., 1990; 2 (1): 71–79. doi: 10.1016/0955-2235(90)90010-h

Chung J.C., Shum-Tim D. Neovascularization in tissue engineering. Cells, 2012; 1 (4): 1246–1260. doi: 10.3390/cells1041246

Nikol S., Baumgartner I., van Belle E., Diehm C., Visoná A., Capogrossi M.C., Ferreira-Maldent N., Gallino A., Graham Wyatt M., Dinesh Wijesinghe L., Fusari M., Stephan D., Emmerich J., Pompilio G., Vermassen F., Pham E., Grek V., Coleman M., Meyer F. Therapeutic angiogenesis with intramuscular nv1fgf improves amputation-free survival in patients with critical limb ischemia. Mol. Ther., 2008; 16 (5): 972–978. doi: 10.1038/mt.2008.33

Mukherjee S., Patra C.R. Therapeutic application of anti-angiogenic nanomaterials in cancers. Nanoscale, 2016; 8 (25): 12444–12470. doi: 10.1039/c5nr07887c

Morishita R., Shimamura M., Takeya Y., Nakagami H., Chujo M., Ishihama T., Yamada E., Rakugi H. Combined analysis of clinical data on HGF gene therapy to treat critical limb ischemia in Japan. Curr. Gene Ther., 2020; 20 (1): 25–35. doi: 10.2174/1566523220666200516171447

Sanada F., Fujikawa T., Shibata K., Taniyama Y., Rakugi H., Morishita R. Therapeutic angiogenesis using HGF plasmid. Ann. Vasc. Dis., 2020; 13 (2): 109–115. doi: 10.3400/avd.ra.20-00035.

Wu J., Heemskerk J.W.M., Baaten C.C.F.M.J. Platelet membrane receptor proteolysis: implications for platelet function. Front. Cardiovasc. Med., 2021; 7: 608391. doi: 10.3389/fcvm.2020.608391

Burzynski L.C., Humphry M., Pyrillou K., Wiggins K.A., Chan J.N.E., Figg N., Kitt L.L., Summers C., Tatham K.C., Martin P.B., Bennett M.R., Clarke M.C.H. The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin. Immunity, 2019; 50 (4): 1033–1042.e6. doi: 10.1016/j.immuni.2019.03.003

Fang X., Liao R., Yu Y., Li J., Guo Z., Zhu T. Thrombin induces secretion of multiple cytokines and expression of protease-activated receptors in mouse mast cell line. Mediators Inflamm., 2019; 2019: 4952131. doi: 10.1155/2019/4952131

Jaberi N., Soleimani A., Pashirzad M., Abdeahad H., Mohammadi F., Khoshakhlagh M., Khazaei M., Ferns G.A., Avan A., Hassanian S.M. Role of thrombin in the pathogenesis of atherosclerosis. J. Cell. Biochem., 2019; 120 (4): 4757–4765. doi: 10.1002/jcb.27771

Bea F., Kreuzer J., Preusch M., Schaab S., Isermann B., Rosenfeld M.E., Katus H., Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2006; 26 (12): 2787–2792. doi: 10.1161/01.ATV.0000246797.05781.ad

Grebe A., Hoss F., Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res., 2018; 122 (12): 1722–1740. doi: 10.1161/CIRCRESAHA.118.311362

Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol., 2013; 13 (6): 397–411. doi: 10.1038/nri3452

Galea J., Armstrong J., Gadsdon P., Holden H., Francis S.E., Holt C.M. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol., 1996; 16 (8): 1000– 1006. doi: 10.1161/ 01.atv.16.8.1000

Weber A., Wasiliew P., Kracht M. Interleukin-1beta (IL-1beta) processing pathway. Sci. Signal, 2010; 3 (105): cm2. doi: 10.1126/scisignal.3105cm2

Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci. Signal, 2010; 3 (105): cm1. doi: 10.1126/scisignal.3105cm1

Beltrami-Moreira M., Vromman A., Sukhova G.K., Folco E.J., Libby P. Redundancy of IL-1 isoform signaling and its implications for arterial remodeling. PLoS One, 2016; 11 (3): e0152474. doi: 10.1371/journal.pone.0152474

Libby P. Collagenases and cracks in the plaque. J. Clin. Invest., 2013; 123 (8): 3201–3203. doi: 10.1172/JCI67526

Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J. Am. Coll. Cardiol., 2017; 70 (18): 2278–2289. doi: 10.1016/j.jacc.2017.09.028

Vromman A., Ruvkun V., Shvartz E., Wojtkiewicz G., Santos Masson G., Tesmenitsky Y., Folco E., Gram H., Nahrendorf M., Swirski F.K., Sukhova G.K., Libby P. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. Eur. Heart J., 2019; 40 (30): 2482–2491. doi: 10.1093/eurheartj/ehz008

Kamari Y., Shaish A., Shemesh S., Vax E., Grosskopf I., Dotan S., White M., Voronov E., Dinarello C.A., Apte R.N., Harats D. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin1α. Biochem. Biophys. Res. Commun., 2011; 405 (2): 197–203. doi: 10.1016/j.bbrc.2011.01.008

Tsioufis P., Theofilis P., Tsioufis K., Tousoulis D. The impact of cytokines in coronary atherosclerotic plaque: current therapeutic approaches. Int. J. Mol. Sci., 2022; 23 (24): 15937. doi: 10.3390/ijms232415937

Dinarello C.A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev., 2018; 281 (1): 8–27. doi: 10.1111/imr.12621

Herder C., de Las Heras Gala T., Carstensen-Kirberg M., Huth C., Zierer A., Wahl S., Sudduth-Klinger J., Kuulasmaa K., Peretz D., Ligthart S., Bongaerts B.W.C., Dehghan A., Ikram M.A., Jula A., Kee F., Pietilä A., Saarela O., Zeller T., Blankenberg S., Meisinger C., Peters A., Roden M., Salomaa V., Koenig W., Thorand B. Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts. Arterioscler. Thromb. Vasc. Biol., 2017; 37 (6): 1222–1227. doi: 10.1161/ATVBAHA.117.309307

Mai W., Liao Y. Targeting IL-1β in the treatment of atherosclerosis. Front. Immunol., 2020; 11: 589654. doi: 10.3389/fimmu.2020.589654

Lee Y.W., Hirani A.A. Role of interleukin-4 in atherosclerosis. Arch. Pharm. Res., 2006; 29 (1): 1–15. doi: 10.1007/BF02977462

Ali M., Girgis S., Hassan A., Rudick S., Becker R.C. Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Coron. Artery Dis., 2018; 29 (5): 429–437. doi: 10.1097/MCA.0000000000000625

Silveira A., McLeod O., Strawbridge R.J., Gertow K., Sennblad B., Baldassarre D., Veglia F., Deleskog A., Persson J., Leander K., Gigante B., Kauhanen J., Rauramaa R., Smit A.J., Mannarino E., Giral P., Gustafsson S., Söderberg S., Öhrvik J., Humphries S.E., Tremoli E., de Faire U., Hamsten A. Plasma IL-5 concentration and subclinical carotid atherosclerosis. Atherosclerosis, 2015; 239 (1): 125–130. doi: 10.1016/j.atherosclerosis.2014.12.046

Ishigami T., Abe K., Aoki I., Minegishi S., Ryo A., Matsunaga S., Matsuoka K., Takeda H., Sawasaki T., Umemura S., Endo Y. Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels. FASEB J., 2013; 27 (9): 3437–3445. doi: 10.1096/fj.12-222653

Zhao W., Lei T., Li H., Sun D., Mo X., Wang Z., Zhang K., Ou H. Macrophage-specific overexpression of interleukin-5 attenuates atherosclerosis in LDL receptor-deficient mice. Gene Ther., 2015; 22 (8): 645–652. doi: 10.1038/gt.2015.33

Ren W., Wang Z., Wang J., Wu Z., Ren Q., Yu A., Ruan Y. IL-5 overexpression attenuates aortic dissection by reducing inflammation and smooth muscle cell apoptosis. Life Sci., 2020; 241: 117144. doi: 10.1016/j.lfs.2019.117144

Reiss A.B., Siegart N.M., de Leon J. Interleukin-6 in atherosclerosis: Atherogenic or atheroprotective? Clin. Lipidol., 2017; 12: 14–23. doi: 10.1080/17584299.2017.1319787

Schaper F., Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth. Factor Rev., 2015; 26 (5): 475–487. doi: 10.1016/j.cytogfr.2015.07.004

Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci., 2012; 8 (9): 1237–1247. doi: 10.7150/ijbs.4989

Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D.O., Fowkes F.G.R. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation, 2005; 112: 976–983. doi: 10.1161/CIRCULATIONAHA.104.513085

Li R., Paul A., Ko K.W., Sheldon M., Rich B.E., Terashima T., Dieker C., Cormier S., Li L., Nour E.A., Chan L., Oka K. Interleukin-7 induces recruitment of monocytes/macrophages to endothelium. Eur. Heart J., 2012; 33 (24): 3114–3123. doi: 10.1093/eurheartj/ehr245

Standiford T.J., Strieter R.M., Allen R.M., Burdick M.D., Kunkel S.L. IL-7 up-regulates the expression of IL-8 from resting and stimulated human blood monocytes. J. Immunol., 1992; 149: 2035–2039.

An Z., Li J., Yu J., Wang X., Gao H., Zhang W., Wei Z., Zhang J., Zhang Y., Zhao J., Liang X.. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages. Cell. Cycle, 2019; 18: 2928–2938. doi: 10.1080/15384101.2019.1662678

Zhang W., Tang T., Nie D., Wen S., Jia C., Zhu Z., Xia N., Nie S., Zhou S., Jiao J., Dong W., Lv B., Xu T., Sun B., Lu Y., Li Y., Cheng L., Liao Y., Cheng X. IL-9 aggravates the development of atherosclerosis in ApoE-/mice. Cardiovasc. Res., 2015; 106 (3): 453–464. doi: 10.1093/cvr/cvv110

Mittal S.K., Cho K.J., Ishido S., Roche P.A. Interleukin 10 (IL-10)-mediated immunosuppression: march-I induction regulates antigen presentation by macrophages but not dendritic cells. J. Biol. Chem., 2015; 290 (45): 27158–27167. doi: 10.1074/jbc.M115.682708

Han X., Boisvert W.A. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb. Haemost., 2015; 113 (3): 505–512. doi: 10.1160/TH14-06-0509

Abu El-Asrar A.M., Ahmad A., Allegaert E., Siddiquei M.M., Gikandi P.W., de Hertogh G., Opdenakker G. Interleukin-11 overexpression and M2 macrophage density are associated with angiogenic activity in proliferative diabetic retinopathy. Ocul. Immunol. Inflamm., 2020; 28 (4): 575–588. doi: 10.1080/09273948.2019.1616772

Roger I., Estornut C., Ballester B., Milara J., Cortijo J. Role of IL-11 in vascular function of pulmonary fibrosis patients. Eur. Respir. J., 2019; 54 (suppl 63): PA1424. doi: 10.1183/13993003.congress-2019.PA1424

Elshabrawy H.A., Volin M.V., Essani A.B., Chen Z., McInnes I.B., van Raemdonck K., Palasiewicz K., Arami S., Gonzalez M., Ashour H.M., Kim S.J., Zhou G., Fox D.A., Shahrara S. IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Angiogenesis, 2018; 21 (2): 215–228. doi: 10.1007/s10456-017-9589-y

Guo Y.T., Lu Y.Y., Lu X., He S., Li S.J., Shao S., Zhou H.D., Wang R.Q., Li X.D., Gao P.J. Krüppellike factor 15/interleukin 11 axis-mediated adventitial remodeling depends on extracellular signal-regulated kinases 1 and 2 activation in angiotensin ii-induced hypertension. J. Am. Heart Assoc., 2021; 10 (16): e020554. doi: 10.1161/JAHA.120.020554

Widjaja A.A., Viswanathan S., Jinrui D., Singh B.K., Tan J., Wei Ting J.G., Lamb D., Shekeran S.G., George B.L., Schafer S., Carling D., Adami E., Cook S.A. Molecular dissection of pro-fibrotic IL11 signaling in cardiac and pulmonary fibroblasts. Front. Mol. Biosci., 2021; 8: 740650. doi: 10.3389/fmolb.2021.740650

Ye J., Wang Y., Wang Z., Liu L., Yang Z., Wang M., Xu Y., Ye D., Zhang J., Lin Y., Ji Q., Wan J. Roles and mechanisms of interleukin-12 family members in cardiovascular diseases: opportunities and challenges. Front. Pharmacol., 2020; 11: 129. doi: 10.3389/fphar.2020.00129

Bobryshev Y.V., Sobenin I.A., Orekhov A.N., Chistiakov D.A. Novel anti-inflammatory interleukin-35 as an emerging target for antiatherosclerotic therapy. Curr. Pharm. Des., 2015 ;21: 1147–1151. doi: 10.2174/1381612820666141014123810

Kan X., Wu Y., Ma Y., Zhang C., Li P., Wu L., Zhang S., Li Y., Du J. Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis. Cardiovasc. Res., 2016; 109 (2): 249–259. doi: 10.1093/cvr/cvv255

Фатхуллина А.Р., Пешкова Ю.О., Кольцова Е.К. Роль цитокинов в развитии атеросклероза. Биохимия, 2016: 81 (11): 1614–1627. doi: 10.1134/S0006297916110134

Fatkhullina A.R., Peshkova I.O., Koltsova E.K. The role of cytokines in the development of atherosclerosis. Biohimia (Mosc)., 2016; 81 (11): 1358–1370. (In Russ.) doi: 10.1134/S0006297916110134

Rossol M., Heine H., Meusch U., Quandt D., Klein C., Sweet M.J., Hauschildt S. LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. Immunol., 2011; 31 (5): 379– 446. doi: 10.1615/critrevimmunol.v31.i5.20

McGeachy M.J., Cua D.J., Gaffen S.L. The IL-17 family of cytokines in health and disease. Immunity, 2019; 50 (4): 892–906. doi: 10.1016/j.immuni.2019.03.021

Kidani Y., Bensinger S.J. Reviewing the impact of lipid synthetic flux on Th17 function. Curr. Opin. Immunol., 2017; 46: 121–126. doi: 10.1016/j.coi.2017.03.012

Danzaki K., Matsui Y., Ikesue M., Ohta D., Ito K., Kanayama M., Kurotaki D., Morimoto J., Iwakura Y., Yagita H., Tsutsui H., Uede T. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012; 32 (2): 273–280. doi: 10.1161/ATVBAHA.111.229997

Erbel C., Dengler T.J., Wangler S., Lasitschka F., Bea F., Wambsganss N., Hakimi M., Böckler D., Katus H.A., Gleissner C.A. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res. Cardiol., 2011; 106 (1): 125–134. doi: 10.1007/s00395-010-0135-y

González L., Rivera K., Andia M.E., Rodriguez G.M. The IL-1 family and its role in atherosclerosis. Int. J. Mol. Sci., 2022; 24 (1): 17. doi: 10.3390/ijms24010017

Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth. Factor Rev., 2010; 21 (5): 345–352. doi: 10.1016/j.cytogfr.2010.08.005

Gabunia K., Ellison S., Kelemen S., Kako F., Cornwell W.D., Rogers T.J., Datta P.K., Ouimet M., Moore K.J., Autieri M.V. IL-19 halts progression of atherosclerotic plaque, polarizes, and increases cholesterol uptake and efflux in macrophages. Am. J. Pathol., 2016; 186 (5): 1361–1374. doi: 10.1016/j.aj-path.2015.12.023

Francis A.A., Pierce G.N. An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Exp. Clin. Cardiol., 2011; 16 (3): 77–86.

Khallou-Laschet J., Varthaman A., Fornasa G., Compain C., Gaston A.T., Clement M., Dussiot M., Levillain O., Graff-Dubois S., Nicoletti A., Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One, 2010; 5 (1): e8852. doi: 10.1371/journal.pone.0008852

Ellison S., Gabunia K., Kelemen S.E., England R.N., Scalia R., Richards J.M., Orr A.W., Traylor J.G. Jr, Rogers T., Cornwell W., Berglund L.M., Goncalves I., Gomez M.F., Autieri M.V. Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler. Thromb. Vasc. Biol., 2013; 33 (10): 2316–2324. doi: 10.1161/ATVBAHA.113.301521

Commins S., Steinke J.W., Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol., 2008; 121 (5): 1108–1111. doi: 10.1016/j.jaci.2008.02.026

Hsieh M.Y., Chen W.Y., Jiang M.J., Cheng B.C., Huang T.Y., Chang M.S. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun., 2006; 7 (3): 234–242. doi: 10.1038/sj.gene.6364291

Xia Q., Xiang X., Patel S., Puranik R., Xie Q., Bao S. Characterisation of IL-22 and interferon-gamma-inducible chemokines in human carotid plaque. Int. J. Cardiol., 2012; 154 (2): 187–189. doi: 10.1016/j.ijcard.2011.10.093

Rattik S., Hultman K., Rauch U., Söderberg I., Sundius L., Ljungcrantz I., Hultgеrdh-Nilsson A., Wigren M., Björkbacka H., Fredrikson G.N., Nilsson J. IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice. Atherosclerosis, 2015; 242 (2): 506–514. doi: 10.1016/j.atherosclerosis.2015.08.006

Luo J.W., Hu Y., Liu J., Yang H., Huang P. Inter-leukin-22: a potential therapeutic target in atherosclerosis. Mol. Med., 2021; 27: 88. doi: 10.1186/s10020-021-00353-9

Che Y., Su Z., Xia L. Effects of IL-22 on cardiovascular diseases. Int. Immunopharmacol., 2020; 81: 106277. doi: 10.1016/j.intimp.2020.106277

Evans B.R., Yerly A., van der Vorst E.P.C., Baumgartner I., Schindewolf S.M.B., Döring Y. Inflammatory mediators in atherosclerotic vascular remodeling. Front. Cardiovasc. Med., 2022; 9: 868934. doi: 10.3389/fcvm.2022.868934

100

Shi L., Ji Qi., Liu L., Shi Y., Lu Z., Ye J., Zeng T., Xue Y., Yang Z., Liu Y., Lu J., Huang Xi., Qin Qi., Li T., Lin Y.-Z. IL-22 produced by Th22 cells aggravates atherosclerosis development in ApoE-/-mice by enhancing DC-induced Th17 cell proliferation. J. Cell. Mol. Med., 2020; 24: 3064–3078. doi: 10.1111/jcmm.14967

101

Wang J., Zhao P., Gao Y., Zhang F., Yuan X., Jiao Y., Gong K. The effects of anti-IL-23p19 therapy on atherosclerosis development in ApoE-/-mice. J. Interferon Cytokine Res., 2019; 39 (9): 564–571. doi: 10.1089/jir.2019.0050

102

Subramanian M., Thorp E., Tabas I. Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ. Res., 2015; 116 (2): e13–e24. doi: 10.1161/CIRCRESAHA.116.304794

103

Fatkhullina A.R., Peshkova I.O., Dzutsev A., Aghayev T., McCulloch J.A., Thovarai V., Badger J.H., Vats R., Sundd P., Tang H.Y., Kossenkov A.V., Hazen S.L., Trinchieri G., Grivennikov S.I., Koltsova E.K. An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity, 2018; 49 (5): 943–957.e9. doi: 10.1016/j.immuni.2018.09.011

104

Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage F.J., Ouyang W. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med., 2008; 14: 282–289.

105

Lee K.-M., Kang H.A., Park M., Lee H.Y., Song M.J., Ko K., Oh J.W., Kang H.S. Interleukin-24 suppresses the growth of vascular smooth muscle cells by inhibiting H(2)O(2)-induced reactive oxygen species production. Pharmacology, 2012; 90 (5-6): 332–341. doi: 10.1159/000343242

106

Mantani P.T., Dunér P., Bengtsson E., Ljungcrantz I., Sundius L., To F., Nilsson J., Björkbacka H., Fredrikson G.N. Interleukin-25 (IL-25) has a protective role in atherosclerosis development in the aortic arch in mice. J. Biol. Chem., 2018; 293 (18): 6791–6801. doi: 10.1074/jbc.RA117.000292

107

Mantani P.T., Dunér P., Bengtsson E., Alm R., Ljungcrantz I., Söderberg I., Sundius L., To F., Nilsson J., Björkbacka H., Fredrikson G.N. IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice. PLoS One, 2015; 10 (1): e0117255. doi: 10.1371/journal.pone.0117255

108

Yoshida H., Hunter C.A. The immunobiology of interleukin-27. Annu. Rev. Immunol., 2015; 33: 417– 443. doi: 10.1146/annurev-immunol-032414-112134

109

Koltsova E.K., Kim G., Lloyd K.M., Saris C.J., von Vietinghoff S., Kronenberg M., Ley K. Interleukin-27 receptor limits atherosclerosis in Ldlr-/-mice. Circ. Res., 2012; 111 (10): 1274–1285. doi: 10.1161/CIRCRESAHA.112.277525

110

Hirase T., Hara H., Miyazaki Y., Ide N., Nishimoto-Hazuku A., Fujimoto H., Saris C.J., Yoshida H., Node K. Interleukin 27 inhibits atherosclerosis via immunoregulation of macrophages in mice. Am. J. Physiol. Heart Circ. Physiol., 2013; 305 (3): H420– Н429. doi: 10.1152/ajpheart.00198.2013

111

Park M.H., Song M.J., Cho M.C., Moon D.C., Yoon D.Y., Han S.B., Hong J.T. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology, 2012; 135 (1): 63–72. doi: 10.1111/j.1365-2567.2011.03513.x

112

Zheng C., Zheng L., Yoo J.K., Guo H., Zhang Y., Guo X., Kang B., Hu R., Huang J.Y., Zhang Q., Liu Z., Dong M., Hu X., Ouyang W., Peng J., Zhang Z. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell, 2017; 169 (7): 1342–1356. doi: 10.1016/j.cell.2017.05.035

113

Nold-Petry C.A., Nold M.F., Zepp J.A., Kim S.H., Voelkel N.F., Dinarello C.A. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc. Natl. Acad. Sci. USA, 2009; 106 (10): 3883–3888. doi: 10.1073/pnas.0813334106

114

Hong J.T., Son D.J., Lee C.K., Yoon D.Y., Lee D.H., Park M.H. Interleukin 32, inflammation and cancer. Pharmacol. Ther., 2017; 174: 127–137. doi: 10.1016/j.pharmthera.2017.02.025

115

Zaidan S.M., Leyre L., Bunet R., Larouche-Anctil E., Turcotte I., Sylla M., Chamberland A., Chartrand-Lefebvre C., Ancuta P., Routy J.P., Baril J.G., Trottier B., MacPherson P., Trottier S., Harris M., Walmsley S., Conway B., Wong A., Thomas R., Kaplan R.C., Landay A.L., Durand M., Chomont N., Tremblay C.L., El-Far M.; Canadian HIV and Aging Cohort Study. Upregulation of IL-32 isoforms in virologically suppressed HIV-infected individuals: potential role in persistent inflammation and transcription from stable HIV-1 reservoirs. J. Acquir. Immune Defic Syndr., 2019; 82 (5): 503–513. doi: 10.1097/QAI.0000000000002185

116

Mohammad-Rezaei M., Ahmadi R., Rafiei A., Khaledifar A., Fattahi S., Samiei-Sefat A., Emami S., Bagheri N. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol. Biol. Rep., 2021; 48 (5): 4263–4271. doi: 10.1007/s11033-021-06441-7

117

Yang Z., Shi L., Xue Y., Zeng T., Shi Y., Lin Y., Liu L. Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. Clin .Chim. Acta, 2019; 497: 104–109. doi: 10.1016/j.cca.2019.07.019

118

Heinhuis B., Popa C.D., van Tits B.L., Kim S.H., Zeeuwen P.L., van den Berg W.B., van der Meer J.W., van der Vliet J.A., Stalenhoef A.F., Dinarello C.A., Netea M.G., Joosten L.A. Towards a role of interleukin-32 in atherosclerosis. Cytokine, 2013; 64 (1): 433–440. doi: 10.1016/j.cyto.2013.05.002

119

Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., Kim J., Kim Y.M., Kwon Y.G. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood, 2009; 114 (14): 3117– 3126. doi: 10.1182/blood-2009-02-203372

120

Cao K., Liao X., Lu J., Yao S., Wu F., Zhu X., Shi D., Wen S., Liu L., Zhou H. IL-33/ST2 plays a critical role in endothelial cell activation and microglia-mediated neuroinflammation modulation. J. Neuroinflammation., 2018; 15 (1): 136. doi: 10.1186/s12974-018-1169-6

121

McLaren J.E., Michael D.R., Salter R.C., Ashlin T.G., Calder C.J., Miller A.M., Liew F.Y., Ramji D.P. IL-33 reduces macrophage foam cell formation. J. Immunol., 2010; 185 (2): 1222–1229. doi: 10.4049/jimmunol.1000520

122

Zhang H.F., Wu M.X., Lin Y.Q., Xie S.L., Huang T.C., Liu P.M., Nie R.Q., Meng Q.Q., Luo N.S., Chen Y.X., Wang J.F. IL-33 promotes IL-10 production in macrophages: a role for IL-33 in macrophage foam cell formation. Exp. Mol. Med., 2017; 49 (11): e388. doi: 10.1038/emm.2017.183

123

Zheng X., Gong L., Zhang S., Wu W. Epicardial adipose tissue thickness and plasma interleukin-35 predict acute myocardial infarction in patients with coronary artery disease. Int. J. Clin. Exp. Med., 2018; 11: 13456–13467.

124

Jia D., Jiang H., Weng X., Wu J., Bai P., Yang W., Wang Z., Hu K., Sun A., Ge J. Interleukin-35 promotes macrophage survival and improves wound healing after myocardial infarction in mice. Circ. Res., 2019; 124 (9): 1323–1336. doi: 10.1161/CIRCRESAHA

125

Liu J., Lin J., He S., Wu C., Wang B., Liu J., Duan Y., Liu T., Shan S., Yang K., Dong N., Ji Q., Huang K., Li D. Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability. Cell. Physiol. Biochem., 2018; 45 (3): 1034– 1050. doi: 10.1159/000487344

126

McCurdy S., Liu C.A., Yap J., Boisvert W.A. Potential role of IL-37 in atherosclerosis. Cytokine, 2017; 122: 154169. doi: 10.1016/j.cyto.2017.09.025

127

Chai M., Ji Q., Zhang H., Zhou Y., Yang Q., Zhou Y., Guo G., Liu W., Han W., Yang L., Zhang L., Liang J., Liu Y., Shi D., Zhao Y. The protective effect of interleukin-37 on vascular calcification and atherosclerosis in apolipoprotein E-deficient mice with diabetes. J. Interferon Cytokine Res., 2015; 35 (7): 530–539. doi: 10.1089/jir.2014.0212

128

Flusberg D.A., Sorger P.K. Surviving apoptosis: life-death signaling in single cells. Trends Cell. Biol., 2015; 25 (8): 446–458. doi: 10.1016/j.tcb.2015.03.003

129

Ślebioda T.J., Kmieć Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm., 2014; 2014: 325129. doi: 10.1155/2014/325129

130

Nash M., McGrath J.P., Cartland S.P., Patel S., Kavurma M.M. Tumour necrosis factor superfamily members in ischaemic vascular diseases. Cardiovasc. Res., 2019; 115 (4): 713–720. doi: 10.1093/cvr/cvz042

131

Mackesy D.Z., Goalstone M.L. Extracellular signal-regulated kinase-5: Novel mediator of insulin and tumor necrosis factor α-stimulated vascular cell adhesion molecule-1 expression in vascular cells. J. Diabetes, 2014; 6 (6): 595–602. doi: 10.1111/1753-0407.12132

132

Hashizume M., Mihara M. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine, 2012; 58 (3): 424–430. doi: 10.1016/j.cyto.2012.02.010

133

Boshuizen M.C., de Winther M.P. Interferons as essential modulators of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2015; 35 (7): 1579–1588. doi: 10.1161/ATVBAHA.115.305464

134

Zhou Q.D., Chi X., Lee M.S., Hsieh W.Y., Mkrtchyan J.J., Feng A.C., He C., York A.G., Bui V.L., Kronenberger E.B., Ferrari A., Xiao X., Daly A.E., Tarling E.J., Damoiseaux R., Scumpia P.O., Smale S.T., Williams K.J., Tontonoz P., Bensinger S.J. Interferon-mediated reprogramming of membrane cholesterol to evade bacterial toxins. Nat. Immunol., 2020; 21 (7): 746–755. doi: 10.1038/s41590-020-0695-4

135

Ranjbaran H., Sokol S.I., Gallo A., Eid R.E., Iakimov A.O, D’Alessio A., Kapoor J.R., Akhtar S., Howes C.J., Aslan M., Pfau S., Pober J.S., Tellides G. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J. Immunol., 2007; 178: 592–604. doi: 10.4049/jimmunol.178.1.592

136

Serralheiro P., Soares A., Costa Almeida C.M., Verde I. TGF-β1 in vascular wall pathology: unraveling chronic venous insufficiency pathophysiology. Int. J. Mol. Sci., 2017; 18 (12): 2534. doi: 10.3390/ijms18122534

137

Chen P.Y., Qin L., Li G., Wang Z., Dahlman J.E., Malagon-Lopez J., Gujja S., Cilfone N.A., Kauffman K.J., Sun L., Sun H., Zhang X., Aryal B., Canfran-Duque A., Liu R., Kusters P., Sehgal A., Jiao Y., Anderson D.G., Gulcher J., Fernandez-Hernando C., Lutgens E., Schwartz M.A., Pober J.S., Chittenden T.W., Tellides G., Simons M.. Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis. Nat. Metab., 2019; 1: 912–926. doi: 10.1038/s42255-019-0102-3

138

Ligi D., Croce L., Mosti G., Raffetto J.D., Mannello F. chronic venous insufficiency: transforming growth factor-β isoforms and soluble endoglin concentration in different states of wound healing. Int. J. Mol. Sci., 2017; 18 (10): 2206. doi: 10.3390/ijms18102206

139

140

Gong D., Shi W., Yi S.-ju, Chen H., Groffen J., Heisterkamp N. TGFβ signaling plays a critical role in promoting alternative macrophage activation BMC. Immunology, 2012; 13: 31. doi: 10.1186/1471-2172-13-31

141

Ramji D.P., Davies T.S. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev., 2015; 26 (6): 673–685. doi: 10.1016/j.cytogfr.2015.04.003

142

Adela R., Banerjee S.K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res., 2015; 2015: 490842. doi: 10.1155/2015/490842

143

Wischhusen J., Melero I., Fridman W.H. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front. Immunol., 2020; 11: 951. doi: 10.3389/fimmu.2020.00951

144

Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Reviews, 2004; 115: 97–204. doi: 10.1016/j.cytogfr.2004.03.007

145

Battegay E. J., Rupp J., Iruela-Arispe L., Sage E.H., Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J. Cell. Biol., 1994; 125: 917–928. doi: 10.1083/jcb.125.4.917

146

Hellberg C., Ostman A., Heldin C.H. PDGF and vessel maturation. Recent Results Cancer Res., 2010; 180: 103–114. doi: 10.1007/978-3-540-78281-0_7

147

Martino M.M., Brkic S., Bovo E., Burger M., Schaefer D.J., Wolff T., Gürke L., Briquez P.S., Larsson H.M., Gianni-Barrera R., Hubbell J.A., Banfi A. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine. Front. Bioeng. Biotechnol., 2015; 3: 45. doi: 10.3389/fbioe.2015.00045

148

Kalra K., Eberhard J., Farbehi N., Chong J.J., Xaymardan M. Role of PDGF-A/B ligands in cardiac repair after myocardial infarction. Front. Cell Dev. Biol., 2021; 9: 669188. doi: 10.3389/fcell.2021.669188

149

Martínez C.E., Smith C., Palma Alvarado V.A. The influence of platelet-derived products on angiogenesis and tissue repair: A concise update. Front. Physiol., 2015; 6: 159973. doi: 10.3389/fphys.2015.00290

150

Kemp S.S., Lin P.K., Sun Z., Castaсo M.A., Yrigoin K., Penn M.R., Davis G.E. Molecular basis for pericyte-induced capillary tube network assembly and maturation. Front. Cell Dev. Biol., 2022; 10: 943533. doi: 10.3389/fcell.2022.943533

151

Stratman A.N., Davis G.E. Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc. Microanal., 2012; 18 (1): 68–80. doi: 10.1017/S1431927611012402

152

Goumans M.J., Ten Dijke P. TGF-β signaling in control of cardiovascular function. Cold Spring. Harb. Perspect. Biol., 2018; 10 (2): a022210. doi: 10.1101/cshperspect.a022210

153

Shah P., Keppler L., Rutkowski J. A review of platelet derived growth factor playing pivotal role in bone regeneration. J. Oral Implantol., 2014; 40 (3): 330–340. doi: 10.1563/AAID-JOI-D-11-00173

154

Bolshakov I.N., Gornostaev L.M., Fominykh O.I., Svetlakov A.V. Synthesis, chemical and biomedical aspects of the use of sulfated chitosan. Polymers (Basel), 2022; 14 (16): 3431. doi: 10.3390/polym14163431

155

Калинин Р.Е., Грязнов С.В., Никифоров А.А., Камаев А.А., Швальб А.П., Слепнев А.А. Полиморфизм гена синтазы азота и эндотелина-1 при хронической венозной недостаточности. Российский медико-биологический вестник имени академика И.П. Павлова, 2015; 16 (4): 97–102. doi: 10.17816/PAVLOVJ2015497-102

Kalinin R.E., Gryaznov S.V., Nikiforov A.A., Kamaev A.A., Shvalb A.P., Slepnev A.A. Nitric oxide synthase and endothelin-1 gene polymorphism in lower limb chronic venous insufficiency. I.P. Pavlov Russian Medical Biological Herald, 2015; 16 (4): 97–102. (In Russ.) doi: 10.17816/PAVLOVJ2015497-102

156

Pavlides S., Gutierrez-Pajares J.L., Katiyar S., Jasmin J.F., Mercier I., Walters R., Pavlides C., Pestell R.G., Lisanti M.P., Frank P.G. Caveolin-1 regulates the anti-atherogenic properties of macrophages. Cell. Tissue Res., 2014; 358 (3): 821–831. doi: 10.1007/s00441-014-2008-4

157

Bednarska-Chabowska D., Adamiec R., Pawlikowski A., Adamiec J. Selected problems of endothelial functions. II. The role of the selectines in the damage of vascular endothelium. Pol. Merkur. Lekarski, 2002; 12: 329–332.

158

Signorelli S.S., Anzaldi M., Libra M., Navolanic P.M., Malaponte G., Mangano K., Quattrocchi C., di Marco R., Fiore V., Neri S. Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology, 2016; 67 (9): 870–874. doi: 10.1177/0003319716633339

159

Al-Ghurabi M.E., Muhi A.A., Al-Mudhafar D.H. Vascular cell adhesion molecule-1 and endothelial leukocyte adhesion molecule-1 as markers of atherosclerosis of NIDDM. Amer. J. Life Sci., 2015; 3 (1): 22–26. doi: 10.11648/j.ajls.20150301.15

160

Tsai M.K., Hsieh C.C., Kuo H.F., Lee M.S., Huang M.Y., Kuo C.H., Hung C.H. Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage. Clin. Exp. Med., 2015; 15 (3): 245–253. doi: 10.1007/s10238-014-0304-7

161

Qiao J.H., Tripathi J., Mishra N.K., Cai Y., Tripathi S., Wang X.P., Imes S., Fishbein M.C., Clinton S.K., Libby P., Lusis A.J., Rajavashisth T.B. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am. J. Pathol., 1997; 150: 1687–1699.

162

Kleinbongard P., Heusch G., Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther., 2010; 127: 295–314. doi: 10.1016/j.pharmthera.2010.05.002

163

Cossette É., Cloutier I., Tardif K., DonPierre G., Tanguay J.F. Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. Mol. Cell. Biochem., 2013; 373 (1-2): 137–147. doi: 10.1007/s11010-012-1482-9.

164

Wang L., Tang C. Targeting platelet in atherosclerosis plaque formation: current knowledge and future perspectives. Int. J. Mol. Sci., 2020; 21: 9760. doi: 10.3390/ijms21249760

165

Folco E.J., Sukhova G.K., Quillard T., Libby P. Moderate hypoxia potentiates interleukin-1β production in activated human macrophages. Circ. Res., 2014; 115 (10): 875–883. doi: 10.1161/CIRCRESA-HA.115.304437

166

Pagano P.J., Gutterman D.D. The adventitia: the outs and ins of vascular disease. Cardiovasc. Res., 2007; 75 (4): 636–639. doi: 10.1016/j.cardiores.2007.07.006

167

Edsfeldt A., Grufman H., Asciutto G., Nitulescu M., Persson A., Nilsson M., Nilsson J., Gonзalves I. Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis, 2015; 241 (2): 443–449. doi: 10.1016/j.atherosclerosis.2015.05.019

168

Voloshyna I., Littlefield M.J., Reiss A.B. Atherosclerosis and interferon-γ: new insights and therapeutic targets. Trends Cardiovasc. Med., 2014; 24 (1): 45–51. doi: 10.1016/j.tcm.2013.06.003

169

Eriksson E.E. Intravital microscopy on atherosclerosis in apolipoprotein e-deficient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions. Circulation, 2011; 124 (19): 2129– 2138. doi: 10.1161/CIRCULATIONAHA.111.030627

170

Fallah A., Sadeghinia A., Kahroba H., Samadi A., Heidari H.R., Bradaran B., Zeinali S., Molavi O. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed. Pharmacother., 2019; 110: 775–785. doi: 10.1016/j.biopha.2018.12.022

171

Stenmark K., Yeager M., Kasmi K.C., Nozik-Grayck E., Gerasimovskaya E.V., Li M. The adventitia: essential regulator of vascular structure and function. Ann. Rev. Pysiol., 2013; 75: 23–47. doi: 10.1146/annurev-physiol-030212-183802

172

Tang W., Liu Z., Si Y. Tunica arterial adventitia: a new exploration in intimal hyperplasia. J. Vasc. Med. Surg., 2013; 1: 108. doi:10.4172/2329-6925.1000108

173

Campbell K.A., Lipinski M.J., Doran A.C., Skaflen M.D., Fuster V., McNamara C.A. Lymphocytes and adventitial immune response in atherosclerosis. Circ. Res., 2012; 110: 889–890. doi: 10.1161/CIR-CRESAHA.111.263186

174

Ogeng’o J., Ominde B.S., Ongeti K., Olabu B., Obimbo M., Mwachaka P. Reappraisal of the structure of arterial tunica adventitia and its involvement in atherosclerosis. Anatomy Journal of Africa, 2020; 6: 824–833. doi: 10.4314/aja.v6i1.150685

175

Ogeng’o J.A., Maseghe P., Ongeti K., Obimbo M., Olabu B. Tunica adventitia of the aorta in an active vascular compartment. Anat. J. Afr., 2015; 4: 617–623

176

Mulligan-Kehoe M.J., Simons M. Vasa vasora in normal and diseased arteries. Circulation, 2014; 129:,2557– 2566. doi: 10.1161/CIRCULATIONAHA.113.007189

177

Fugundes A., Pereira A.H., Correa K., de Oliveira M.T., Rodriguez R. Effects of removal of the adventitia of the descending aorta and structural alterations in the tunica media in pigs. Rev. Col. Bras. Circ., 2012; 39: 133–138.

178

Wang J.L., Ma S.Q., Li L., Liu G.Q., Hu W.C., Ma R. Correlation of inflammatory cells in adventitia and formation and extending of atherosclerotic lesions in coronary artery of apolipoprotein E Knockout mice. Chin. J. Physiol., 2013; 56: 77–82. doi: 10.4077/CJP.2013.BAA080

179

Tian J., Hu S., Sun Y., Yu H., Han X., Cheng W., Ban X., Zhang S., Yu B., Jang I.K. Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast enhanced ultrasound imaging and intravascular ultrasound study. Heart, 2013; 99: 48–54. doi: 10.1136/heartjnl-2012-302775

180

Fitzgibbons T.P., Czech M.P. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J. Am. Heart Assoc., 2014; 3: e000582. doi: 10.1161/jaha.113.000582

181

Huh J.Y., Park Y.J., Ham M., Kim J.B. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol. Cells, 2014; 37: 365–371. doi: 10.14348/molcells.2014.0074

The authors declare that there are no conflicts of interest present.